102 related articles for article (PubMed ID: 15995635)
21. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
Tuttle RM; Leboeuf R; Robbins RJ; Qualey R; Pentlow K; Larson SM; Chan CY
J Nucl Med; 2006 Oct; 47(10):1587-91. PubMed ID: 17015892
[TBL] [Abstract][Full Text] [Related]
22. [Recent progress in radionuclide therapy].
Kasagi K; Iwata M; Misaki T; Konishi J; Sakahara H
Nihon Igaku Hoshasen Gakkai Zasshi; 2000 Nov; 60(13):729-37. PubMed ID: 11140321
[TBL] [Abstract][Full Text] [Related]
23. Radioiodine therapy of metastatic lesions of differentiated thyroid cancer.
Luster M; Hänscheid H; Freudenberg LS; Verburg FA
J Endocrinol Invest; 2012; 35(6 Suppl):21-9. PubMed ID: 23014070
[TBL] [Abstract][Full Text] [Related]
24. I-131 activities as high as safely administrable (AHASA) for the treatment of children and adolescents with advanced differentiated thyroid cancer.
Verburg FA; Biko J; Diessl S; Demidchik Y; Drozd V; Rivkees SA; Reiners C; Hänscheid H
J Clin Endocrinol Metab; 2011 Aug; 96(8):E1268-71. PubMed ID: 21613356
[TBL] [Abstract][Full Text] [Related]
25. Decreased uptake after fractionated ablative doses of iodine-131.
Wu HS; Hseu HH; Lin WY; Wang SJ; Liu YC
Eur J Nucl Med Mol Imaging; 2005 Feb; 32(2):167-73. PubMed ID: 15351912
[TBL] [Abstract][Full Text] [Related]
26. Faster radioiodine washout in the treatment of pulmonary metastases of papillary thyroid cancer prepared with recombinant human thyroid-stimulating hormone.
Hung GU; Ho M; Kao CH
Clin Nucl Med; 2009 May; 34(5):316-7. PubMed ID: 19387216
[No Abstract] [Full Text] [Related]
27. Radioiodine therapy in differentiated thyroid cancer: a nuclear medicine perspective.
Clarke SE
Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):430-7. PubMed ID: 20537878
[No Abstract] [Full Text] [Related]
28. Dosimetry in the therapy of metastatic differentiated thyroid cancer administering high 131I activity: the experience of Busto Arsizio Hospital (Italy).
Bianchi L; Baroli A; Lomuscio G; Pedrazzini L; Pepe A; Pozzi L; Chiesa C
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):515-21. PubMed ID: 23358404
[TBL] [Abstract][Full Text] [Related]
29. Treatment of micronodular lung metastases of papillary thyroid cancer: are the tumors too small for effective irradiation from radioiodine?
Sisson JC; Jamadar DA; Kazerooni EA; Giordano TJ; Carey JE; Spaulding SA
Thyroid; 1998 Mar; 8(3):215-21. PubMed ID: 9545107
[TBL] [Abstract][Full Text] [Related]
30. [Effect of radio therapy on the magnitude of iodine radioisotope half-life in the thyroid tissue remnants in patients with differentiated thyroid cancer].
Kozak OV; Trembach OM; Romanenko LV; Butrym OI
Lik Sprava; 2008; (5-6):17-23. PubMed ID: 19253734
[TBL] [Abstract][Full Text] [Related]
31. Redifferentiating agents in non-radioiodine avid cancer.
Seregni E; Vellani C; Castellani MR; Maccauro M; Pallotti F; Scaramellini G; Guzzo M; Greco A
Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):513-9. PubMed ID: 19910904
[TBL] [Abstract][Full Text] [Related]
32. New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era.
Capdevila J; Argiles G; Rodriguez-Frexinos V; Nuñez I; Tabernero J
Discov Med; 2010 Feb; 9(45):153-62. PubMed ID: 20193642
[TBL] [Abstract][Full Text] [Related]
33. Management of 131I therapy for thyroid cancer: cumulative dose from in-patients, discharge planning and personnel requirements.
Pacilio M; Bianciardi L; Panichelli V; Argirò G; Cipriani C
Nucl Med Commun; 2005 Jul; 26(7):623-31. PubMed ID: 15942483
[TBL] [Abstract][Full Text] [Related]
34. Pulmonary fibrosis in youth treated with radioiodine for juvenile thyroid cancer and lung metastases after Chernobyl.
Hebestreit H; Biko J; Drozd V; Demidchik Y; Burkhardt A; Trusen A; Beer M; Reiners C
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1683-90. PubMed ID: 21626048
[TBL] [Abstract][Full Text] [Related]
35. Comparative serum proteomic analysis identified afamin as a downregulated protein in papillary thyroid carcinoma patients with non-131I-avid lung metastases.
Song HJ; Xue YL; Qiu ZL; Luo QY
Nucl Med Commun; 2013 Dec; 34(12):1196-203. PubMed ID: 24089082
[TBL] [Abstract][Full Text] [Related]
36. The Result of Multiple I-131 Treatments on the Effective Half-Life of Retained Radioactivity in Patients Ablated for Differentiated Thyroid Cancer: Possible Evidence for Thyroid Remnant Function Impairment.
Okkalides D
Cancer Biother Radiopharm; 2016 Mar; 31(2):58-64. PubMed ID: 26986816
[TBL] [Abstract][Full Text] [Related]
37. Peace of mind for patients with differentiated thyroid cancer?
Vrachimis A; Riemann B; Gerss J; Maier T; Schober O
Nuklearmedizin; 2013; 52(4):115-20. PubMed ID: 23801296
[TBL] [Abstract][Full Text] [Related]
38. ¹³¹I sodium-iodide versus ⁵⁶Fe surgical steel. Which is better for lateral lymph node metastases in differentiated thyroid cancer patients?
Verburg F; Weber T; Luster M
Nuklearmedizin; 2013; 52(4):113-4. PubMed ID: 23928980
[No Abstract] [Full Text] [Related]
39. [Redifferentiation therapy with rosiglitazone in a case of differentiated thyroid cancer with pulmonary metastases and absence of radioiodine uptake].
Elola M; Yoldi A; Emparanza JI; Matteucci T; Bilbao I; Goena M
Rev Esp Med Nucl; 2011; 30(4):241-3. PubMed ID: 21334106
[TBL] [Abstract][Full Text] [Related]
40. The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma.
Thies ED; Tanase K; Maeder U; Luster M; Buck AK; Hänscheid H; Reiners C; Verburg FA
Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2281-90. PubMed ID: 25030619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
